Biosplice Therapeutics

Focus: Biosplice Therapeutics is a San Diego-based biotech company focused on small molecules that act on stem cells for cell therapy applications. The company operates across multiple therapeutic areas including orthopedic, oncologic, and dermatologic indications.

Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Biosplice Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Biosplice Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Not applicable

Osteoarthritis

N/A

Clinical Trials (1)

NCT02951026An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

N/A

Help build intelligence for Biosplice Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline with 24 active programs spanning Phase 1-3, including three Phase 3 programs (Lorecivivint for knee OA) offering near-term catalysts
Differentiated platform targeting stem cell biology in large markets (osteoarthritis, pulmonary fibrosis, oncology) with multiple shots on goal
San Diego location with access to established biotech talent pools and venture ecosystem

Watch Out For

Zero active job postings signals potential hiring freeze or early-stage execution challenges despite active pipeline
Limited public financial transparency (no revenue, funding, or employee count disclosed) raises uncertainty about company stability and growth trajectory

Generated by Claude from Biosplice Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SM04755

Tendinopathy

PHASE_1

Clinical Trials (1)

NCT03502434A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

Phase 1

SM08502

Solid Tumor, Adult

PHASE_1

Clinical Trials (1)

NCT03355066A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Phase 1

SM04755

Tendinopathy

PHASE_1

Clinical Trials (1)

NCT03229291A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

Phase 1

Lorecivivint

Drug-Drug Interaction

PHASE_1

Clinical Trials (1)

NCT04598542Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Phase 1

SM04690

Degenerative Disc Disease

PHASE_1

Clinical Trials (1)

NCT03246399A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

Phase 1

SM08502

Castration-resistant Prostate Cancer

PHASE_1

Clinical Trials (1)

NCT05084859A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Phase 1

SM04690, 0.03mg/2mL

Moderate to Severe Osteoarthritis

PHASE_1

Clinical Trials (1)

NCT02095548Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

Phase 1

SM04755

Colorectal Cancer

PHASE_1

Clinical Trials (1)

NCT02191761Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

Phase 1

Cirtuvivint

Small-cell Lung Cancer

PHASE_1_2

Clinical Trials (1)

NCT07155200Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Phase 1/2

SM04690

Knee Osteoarthritis

PHASE_2

Clinical Trials (1)

NCT03122860A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Phase 2

lorecivivint

Knee Osteoarthritis

PHASE_2

Clinical Trials (1)

NCT03706521MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis

Phase 2

Topical SM04554 solution

Androgenetic Alopecia

PHASE_2

Clinical Trials (1)

NCT02503137A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Phase 2

SM04690

Osteoarthritis

PHASE_2

Clinical Trials (1)

NCT02536833A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Phase 2

SM04646

Idiopathic Pulmonary Fibrosis

PHASE_2

Clinical Trials (1)

NCT03591926A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

SM04554

Androgenetic Alopecia

PHASE_2

Clinical Trials (1)

NCT02275351A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Phase 2

Cirtuvivint

Soft Tissue Sarcoma (STS)

PHASE_2

Clinical Trials (1)

NCT07032285Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

Phase 2

Placebo

Knee Osteoarthritis

PHASE_2

Clinical Trials (1)

NCT03727022Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Phase 2

Topical SM04554 solution

Androgenetic Alopecia

PHASE_2_3

Clinical Trials (1)

NCT03742518A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

Phase 2/3

Lorecivivint

Osteoarthritis of the Knee

PHASE_3

Clinical Trials (1)

NCT049316673-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

Phase 3

Lorecivivint

Knee Osteoarthritis

PHASE_3

Clinical Trials (1)

NCT04385303Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

Phase 3

Lorecivivint

Knee Osteoarthritis

PHASE_3

Clinical Trials (1)

NCT05603754A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)

Phase 3

Lorecivivint

Knee Osteoarthritis

PHASE_3

Clinical Trials (1)

NCT03928184Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis

Phase 3

Placebo

Osteoarthritis, Knee

PHASE_3

Clinical Trials (1)

NCT04520607A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee